In late 1994 and early 1995 
change appreciably in the wild.
The 1995 epidemic of Ebola (EBO) virus disease in Zaire (1) , coupled with the discovery of an EBO virus in the Ivory Coast in late 1994 (2) , has sparked new scientific and public interest in these mysterious and highly pathogenic viruses. EBO viruses are nonsegmented negative-strand RNA viruses that are genetically related to, but distinct from, the Marburg (MBG) virus (3) . These viruses, classified in the genus Filovirus in the family Filoviridae, cause a severe hemorrhagic disease in human and nonhuman primates (4, 5) . The EBO group of filoviruses comprises three discrete subtypes: Zaire, Sudan, and Reston (EBO-Z, EBO-S, and EBO-R, respectively). In late November 1994, EBO (1, 6) . This epidemic was caused by a strain of EBO-Z, the most pathogenic subtype of EBO virus, which had not been reported for 18 years.
The virion surface glycoproteins (GPs) of filoviruses are multimers of a single structural GP; they are important in the binding of virions to cell receptors and virus entry into the cell cytoplasm (3) . This protein is expressed from the GP gene, which in the genomes of filoviruses is positioned fourth (from the 3' end) of seven linearly arranged genes (3, 7) . Filovirus GPs are highly glycosylated, containing both N-linked and
The publication costs of this article were defrayed in part by page charge payment. This article must therefore be hereby marked "advertisement" in accordance with 18 U.S.C. §1734 solely to indicate this fact. 0-linked carbohydrates (3, (8) (9) (10) that contribute from onethird to one-half of their relatively large molecular weight (Mr -130-170 kDa).
To better define the relationship of EBO viruses to one another, we (1996) 3603 of pUC18 or pSP73/pSP72 vectors (Promega) and cloned as previously described (14) . Sequencing of cloned plasmid preparations was performed using the dideoxy chain termination method (15 treated with 100 j/u 1% SDS for 1 min, followed by the addition of 900 ,jl 1.1 x TNE buffer (1x TNE = 10 mM Tris-HCl/150 mM NaCl/3 mM EDTA, pH 7.6) containing 1.1% Nonidet P-40, 0.55% sodium deoxycholate, and 1.1 mM phenylmethylsulfonyl fluoride (PMSF). Triton X-100 treatment was performed by the addition of 1 x TNE containing 1% Triton X-100 and 1 mM PMSF to cells;
TCFwas made to 1% with Triton X-100 and to 1 mM PMSF. RIP assays were performed on 500 ,ul of solutions as described (14) . Antibodies used in RIP assays were: (i) an anti-EBO-R GP/ small/secreted glycoprotein precursor (SGP) monoclonal antibody (high-titered mouse ascitic fluid; cross-reactive with GP and SGP) prepared essentially as described (16) , and (ii) a high-titered polyclonal mouse anti-EBO-Z GP produced against a GP expressed by a recombinant baculovirus (10) . Endoglycosidase digestion of RIP products was performed as described elsewhere (17) .
Computer region (Fig. 2) where more than half of the potential N-linked glycosylation sites and the putative region for 0-linked glycosylation are located. The rest of the GP sequence is conserved and is more hydrophobic. In addition, all the cysteine residues in the SGP and GP are conserved (see asterisks in Fig. 2 ). One common feature found in the GPs of all filoviruses is a highly conserved immunosuppressive motif (26 residues) in the Cterminal third of the GP that has a high degree of homology to those found in the envelope glycoproteins of oncogenic retroviruses (9, 18) .
Since sequence analysis indicated that the GPs of EBO viruses are encoded in two frames, it was important to determine the mechanism(s) by which the GP is expressed. The original published description of the EBO-Z (Yambuku/ 1976/057935) GP gene (7) was based on a virus stock that had undergone three rounds of plaque purification and was later determined to contain a single base insertion (extra uridine nucleotide) that joined the GP frames. Because a single base insertion led to the connecting of the frames in the mutant (plaque purified) EBO-Z, it was thought that RNA editing at or near this site, in a manner similar to that described for the P genes of paramyxoviruses (19) (Fig. 3A, lanes 5-8) . The Proc. Natl. Acad. Sci. USA 93 (1996) GP1 I* 8) , or mock-infected cell supernatant fluids (lanes 9 and 10). Lanes 5, 7, and 9 contain products derived from lysates prepared by SDS treatment (followed by Nonidet P-40 and deoxycholate), and lanes 6, 8, and 10 were treated with Triton X-100 (13) . At The secreted EBO-R SGP ranges in size from 50 to 70 kDa, with the central major band estimated to be 59 kDa. Endoglycosidase digestion indicated that at least three major species are present (Fig. 3B) . Removal of all N-linked glycans by Endo F/NF produced two bands, a smaller predominant species and a weaker larger band that may contain 0-linked glycans or represents some other form of the SGP. The SGP found in the supernatant fluids of cells infected with EBO-Z and EBO-S are comparable with those seen with EBO-R (Fig. 3C) . The EBO-Z strains showed strong bands that correspond to the GP and SGP described above for EBO-R, but cross-reactivity of the anti-EBO-Z GP with the EBO-S and EBO-R subtypes resulted in much weaker and thinner bands. Surprisingly, the Zaire subtypes produced a third glycosylated protein band (-24 kDa) of unknown origin. Fig. 3D shows that the SGP of EBO-R is absent from purified virion preparations (as is the case for the other EBO subtypes) and is thus a nonstructural protein. As A detailed phylogenetic profile of the family Filoviridae was determined using nucleotide sequences that encode N-and C-terminal regions of the GP. These regions contained sufficient homology to allow accurate nucleotide alignment. Maximum parsimony analysis of these sequences produced a single most parsimonious tree that clearly separated EBO and MBG viruses and divided the EBO subtypes into four distinct clades (Fig. 4) .
DISCUSSION
The finding that all EBO subtypes encode their structural (virion) GPs in two frames and that expression of these GPs occurs through transcriptional editing is highly unusual. Our results indicated that there was no sequence variation in the EBO vRNA corresponding to the mRNA editing site when analyzed directly from the blood of an acutely infected human. Proc. Natl. Acad. Sci. USA 93 (1996) 
